The most well-known example of a successful synthetic lethality approach is the case of PARP inhibitors as ovarian cancer treatment, particularly in the case of BRCA1/2 deficient cells, which are defective in both HR and ICL repair [174]. The gene discussed is BRCA1; the disease is ovarian carcinoma.